230 related articles for article (PubMed ID: 34117648)
1. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
[TBL] [Abstract][Full Text] [Related]
3. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
[TBL] [Abstract][Full Text] [Related]
4. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
[TBL] [Abstract][Full Text] [Related]
6. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
[TBL] [Abstract][Full Text] [Related]
8. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
Alsultan A; An G; Peloquin CA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3800-7. PubMed ID: 25870068
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
Ghimire S; Van't Boveneind-Vrubleuskaya N; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Wilffert B; Touw DJ; Alffenaar JW
J Antimicrob Chemother; 2016 Oct; 71(10):2691-703. PubMed ID: 27231277
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization.
Cao G; Zhang J; Wu X; Yu J; Chen Y; Ye X; Zhu D; Zhang Y; Guo B; Shi Y
J Clin Pharm Ther; 2013 Oct; 38(5):394-400. PubMed ID: 23701411
[TBL] [Abstract][Full Text] [Related]
11. Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.
Al-Shaer MH; Märtson AG; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Houpt ER; Ashkin D; Griffith DE; Cegielski JP; Heysell SK; Peloquin CA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631828
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin.
Jaruratanasirikul S; Jaspattananon A; Wongpoowarak W; Nawakitrangsan M; Thengyai S; Samaeng M
J Med Assoc Thai; 2018 Aug; 99(8):886-92. PubMed ID: 29947489
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
Mase SR; Jereb JA; Gonzalez D; Martin F; Daley CL; Fred D; Loeffler AM; Menon LR; Bamrah Morris S; Brostrom R; Chorba T; Peloquin CA
Pediatr Infect Dis J; 2016 Apr; 35(4):414-21. PubMed ID: 26658531
[TBL] [Abstract][Full Text] [Related]
14. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
15. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
[TBL] [Abstract][Full Text] [Related]
17. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
Van't Boveneind-Vrubleuskaya N; Seuruk T; van Hateren K; van der Laan T; Kosterink JGW; van der Werf TS; van Soolingen D; van den Hof S; Skrahina A; Alffenaar JC
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507117
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
